The layoffs come as the drugmaker works to revise its research and development strategy under its new R&D chief Hal Barron.
Most of the job cuts will affect chemists at its facility in Upper Providence, Pa., as well as some administrative roles.
A few R&D jobs at its facility in Stevenage, U.K., also will be eliminated.
Read the full report here.
More articles on pharmacy:
PBM hearing should prompt bill to ban ‘secrecy’ in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.